Table 3.

Univariate analysis and multivariate analysis

Univariate Analysis
Factor	PFS			OS
	P-value	Hazard Ratio (HR)	95%CI: HR	P-value	HR	95% CI: HR
Age	<0.001	0.41	0.31–0.56	<0.001	0.27	0.19–0.38
≤48 y
>48 y
KPS	0.03	0.71	0.52–0.97	<0.001	0.46	0.33–0.64
≥90
<90
Surgical procedurea	0.36	0.85	0.60–1.21	0.54	0.88	0.60–1.31
Adjuvant therapyb	<0.001	0.62	0.54–0.71	<0.001	0.49	0.42–0.58
WHO gradec	<0.001	0.44	0.36–0.53	<0.001	0.31	0.25–0.39
IDH 1/2 mutationd	<0.001	0.17	0.12–0.23	<0.001	0.09	0.06–0.14
18FET-negative vs positive	0.01	0.58	0.38–0.89	0.001	0.39	0.22–0.69
TBRmax	<0.001	0.47	0.35–0.64	<0.001	0.47	0.34–0.66
≤2.6
>2.6
TTPmin	<0.001	0.29	0.20–0.42	<0.001	0.14	0.08–0.24
>17.5 min
≤17.5 min
CE	<0.001	0.45	0.33–0.63	<0.001	0.34	0.23–0.48
No
Yes
T2 volume	0.10	0.78	0.58–1.04	0.39	0.87	0.62–0.83
≤49 mL
>49 mL
Multivariate analysis
Factor	PFS			OS
	P-value	HR	95% CI: HR	P-value	HR	95% CI: HR
Age	0.80	0.95	0.65–1.40	0.11	0.71	0.47–1.07
≤48 y
>48 y
KPS	0.49	0.94	0.78–1.12	0.75	0.95	0.69–1.31
≥90
<90
Adjuvant therapyb	0.23	0.85	0.66–1.11	0.24	0.87	0.61–1.13
WHO gradec	0.04	0.65	0.44–0.97	0.007	0.52	0.33–0.84
IDH 1/2 mutationd	<0.001	0.24	1.15–0.40	<0.001	0.19	0.11–0.34
TBRmax	0.08	0.70	0.47–1.05	0.72	0.93	0.59–1.43
≤2.6
>2.6
TTPmin	0.19	0.72	0.44–1.18	0.01	0.43	0.22–0.82
>17.5 min
≤17.5 min
CE	0.83	0.95	0.61–1.49	0.22	0.71	0.42–1.22
No
Yes

a: surgery vs biopsy; b: adjuvant therapy: wait-and-see vs chemotherapy vs radiation vs radiochemotherapy; c: WHO grade II vs III vs IV; d: IDH1/2 mut vs IDH wt.